Ascletis Pharma Inc./歌礼生物科技（杭州)有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne 2021-08-09 08:30
Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) 2021-07-28 08:30
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma 2021-07-22 08:30
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China 2021-07-13 08:30
Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist 2021-06-16 21:00
Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication 2021-06-07 08:30
Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication 2021-05-27 08:30
Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA 2021-05-25 08:30
Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) 2021-05-05 08:30
Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41 2021-04-14 20:00
Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021 2021-04-12 08:30
Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors 2021-03-30 08:00
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH 2021-03-09 08:30
Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH 2021-02-25 08:30
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41 2021-02-21 19:30
Ascletis Joins Sagimet's US$80 Million in Crossover Financing with Premium Investors 2021-02-11 22:30
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41 2021-01-12 08:30
First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial 2020-12-28 08:30
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial 2020-12-22 19:18
Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42，an FXR Agonist 2020-12-14 08:30
1 4 5 6 7 8 9